National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- (-) Adverse Drug Events (ADE) (5)
- Adverse Events (2)
- Blood Thinners (1)
- Cardiovascular Conditions (1)
- Diabetes (1)
- Digestive Disease and Health (1)
- Elderly (1)
- Heart Disease and Health (1)
- Medication (5)
- Medication: Safety (1)
- (-) Patient-Centered Healthcare (5)
- Patient-Centered Outcomes Research (1)
- Patient Safety (1)
- Registries (1)
- Risk (2)
- Shared Decision Making (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 5 of 5 Research Studies DisplayedMentias A, Briasoulis A, Shantha G
Impact of heart failure type on thromboembolic and bleeding risk in patients with atrial fibrillation on oral anticoagulation.
Differential impact of heart failure (HF) category on thromboembolic and bleeding risk in atrial fibrillation (AF) patients on oral anticoagulation (OAC) is unknown. In this study, the investigators used Medicare data for beneficiaries with new AF diagnosed between 2011 and 2013 to identify patients with HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), and no HF. The investigators concluded that in AF patients, HFrEF and HFpEF are both associated with higher risk of ischemic stroke, HF and AMI admissions, even after adjusting for OAC use, compared with patients without HF.
AHRQ-funded; HS023104.
Citation: Mentias A, Briasoulis A, Shantha G .
Impact of heart failure type on thromboembolic and bleeding risk in patients with atrial fibrillation on oral anticoagulation.
Am J Cardiol 2019 May 15;123(10):1649-53. doi: 10.1016/j.amjcard.2019.02.027..
Keywords: Heart Disease and Health, Cardiovascular Conditions, Blood Thinners, Medication, Adverse Drug Events (ADE), Adverse Events, Risk, Elderly, Patient-Centered Healthcare, Registries
Lee JL, Dy SM, Gurses AP
Towards a more patient-centered approach to medication safety.
In this perspective, the authors focus their discussion on a patient-centered approach to measurement and describe commonly used health system–oriented medication safety measures for evaluating interventions. They also discuss measures that reflect patient-centeredness in medication safety.
AHRQ-funded; HS024436.
Citation: Lee JL, Dy SM, Gurses AP .
Towards a more patient-centered approach to medication safety.
J Patient Exp 2018 Jun;5(2):83-87. doi: 10.1177/2374373517727532..
Keywords: Adverse Drug Events (ADE), Patient-Centered Healthcare, Patient Safety, Medication: Safety, Medication
Dulai PS, Siegel CA
Optimization of drug safety profile in inflammatory bowel disease through a personalized approach.
Treatment strategies and treatment options have changed considerably over the past decade for Inflammatory Bowel Disease (IBD). In this review the authors discuss the potential risks of therapy in IBD, opportunities to mitigate those risks, and a personalized approach to consider when using these agents in clinical practice.
AHRQ-funded; HS021747.
Citation: Dulai PS, Siegel CA .
Optimization of drug safety profile in inflammatory bowel disease through a personalized approach.
Curr Drug Targets 2018;19(7):740-47. doi: 10.2174/1389450118666170525114939..
Keywords: Adverse Drug Events (ADE), Adverse Events, Shared Decision Making, Digestive Disease and Health, Medication, Patient-Centered Healthcare
Bavishi AA, Grammer LC, Pongracic J
Diurnal variations in subcutaneous allergen immunotherapy reactions.
The investigators sought to assess whether the timing of subcutaneous immunotherapy (SCIT) affects the rate of adverse reactions. They found that afternoon and evening injections of SCIT are associated with increased cutaneous reaction rates when compared with morning injections, recommending the administration of SCIT in the morning in patients experiencing bothersome local reactions.
AHRQ-funded; HS023011.
Citation: Bavishi AA, Grammer LC, Pongracic J .
Diurnal variations in subcutaneous allergen immunotherapy reactions.
Ann Allergy Asthma Immunol 2017 Jan;118(1):103-07. doi: 10.1016/j.anai.2016.10.007.
.
.
Keywords: Adverse Drug Events (ADE), Medication, Patient-Centered Healthcare, Patient-Centered Outcomes Research
McCoy RG, Lipska KJ, Yao X
Intensive treatment and severe hypoglycemia among adults with type 2 diabetes.
The objectives of this study were to estimate the prevalence of intensive treatment and the association between intensive treatment, clinical complexity, and incidence of severe hypoglycemia among adults with type 2 diabetes who are not using insulin. The researchers found that over 20% of patients with type 2 diabetes received intensive treatment that might have been unnecessary and that among patients with high clinical complexity, intensive treatment nearly doubled the risk of severe hypoglycemia.
AHRQ-funded; HS018339.
Citation: McCoy RG, Lipska KJ, Yao X .
Intensive treatment and severe hypoglycemia among adults with type 2 diabetes.
JAMA Intern Med 2016 Jul;176(7):969-78. doi: 10.1001/jamainternmed.2016.2275.
.
.
Keywords: Adverse Drug Events (ADE), Diabetes, Medication, Patient-Centered Healthcare, Risk